TP-0903 is primarily investigated for its potential therapeutic application in oncology, specifically as a selective inhibitor of the AXL receptor tyrosine kinase. AXL signaling is implicated in tumor progression, metastasis, and resistance to chemotherapy and targeted therapies. By inhibiting AXL, TP-0903 may help suppress cancer cell survival, reduce tumor spread, and enhance the effectiveness of other anticancer agents. It has shown promise in preclinical models of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and other advanced malignancies where AXL overexpression correlates with poor prognosis. TP-0903’s design aims to improve potency and selectivity, potentially overcoming limitations of earlier AXL inhibitors. Currently, TP-0903 is under clinical evaluation to determine its safety, pharmacokinetics, and efficacy as a monotherapy and in combination with other agents such as immune checkpoint inhibitors or chemotherapy. Its development represents a strategy to target tumor microenvironment interactions and drug resistance mechanisms in hard-to-treat cancers.